Results 21 to 30 of about 365,877 (337)
Cancer Management and Research, 2023 Wei-Fan Ou,1 Pei-Ya Liao,1 Yu-Wei Hsu,2,3 Yen-Hsiang Huang,1,4– 6 Kuo-Hsuan Hsu,6,7 Jeng-Sen Tseng,1,4– 6,8 Gee-Chen Chang,4,9– 11 Tsung-Ying Yang1,6,12 1Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital ...
Ou WF +7 more
doaj
Cancer Research, Statistics, and Treatment, 2019 Non-small-cell lung cancer (NSCLC) constitutes 85% of patients diagnosed with lung cancer. In metastatic cases, its treatment classically consists of systemic cytotoxic chemotherapy, which resulted in a median overall survival of 7.9 months.
Akhil Rajendra +5 more
doaj +1 more source
Non-small-cell lung cancer metastasis to unusual sites: A retrospective case series
Cancer Research, Statistics, and Treatment, 2021 Background: The majority of all lung cancers are non-small-cell lung cancers (NSCLCs). They usually spread to the pleura, brain, adrenal gland, lungs, liver, and bones.
Sandip Ganguly +6 more
doaj +1 more source
The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: A systematic review and meta-analysis [PDF]
, 2019 Background The brain is a common site for metastasis in non-small-cell lung cancer (NSCLC). This study was designed to evaluate the relationship between the mutational of the epidermal growth factor receptor (EGFR) and overall survival (OS) in NSCLC ...
Han, Yunan +11 more
core +2 more sources
Therapeutic Sequencing in ALK+ NSCLC [PDF]
Pharmaceuticals, 2021 Anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK+ NSCLC) is a model disease for the use of targeted pharmaceuticals in thoracic oncology. Due to higher systemic and intracranial efficacy, the second-generation ALK tyrosine kinase inhibitors (TKI) alectinib and brigatinib have irrevocably displaced crizotinib as standard first-line ...
Mei Elsayed, Petros Christopoulos
openaire +3 more sources
Salivary cytokine panel indicative of non-small cell lung cancer. [PDF]
, 2018 Objective To develop a combinatorial panel of salivary cytokines that manifests the presence of non-small cell lung cancer (NSCLC) that will eventually improve prognosis by facilitating the early diagnosis and management of this common cancer. Methods We
Koizumi, Tomonobu +2 more
core +3 more sources
Cancer Biology & Medicine, 2022 Objective: The novel compound GCJ-490A has been discovered as a pan-histone deacetylase (HDAC) inhibitor that exerts potent inhibitory activity against HDAC1, HDAC3, and HDAC6.
Ting He +7 more
doaj +1 more source
Management of Febrile Neutropenia - a German Prospective Hospital Cost Analysis in Lymphoproliferative Disorders, Non-Small Cell Lung Cancer, and Primary Breast Cancer [PDF]
, 2011 Background: Febrile neutropenia/leukopenia (FN/FL) is the most frequent dose-limiting toxicity of myelosuppressive chemotherapy, but German data on economic consequences are limited.
Angela Ihbe-Heffinger +19 more
core +1 more source
Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study [PDF]
, 2018 Purpose: Abemaciclib, a dual inhibitor of cyclin-dependent kinases 4 and 6, has demonstrated preclinical activity in non–small cell lung cancer (NSCLC).
Beckmann, Richard +16 more
core +2 more sources
Cancer Management and Research, 2022 Xiuming Huang,* Mingfang Huang,* Minbiao Chen, Xianshan Chen Department of Thoracic Surgery, Hainan General Hospital, Haikou, Hainan, 570311, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xianshan ...
Huang X, Huang M, Chen M, Chen X
doaj